Betta Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Chemoradiotherapy
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT02215356
- Locations
- 🇨🇳
Beijing Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Dongguan City People's Hospital, Dongguan, Guangdong, China
🇨🇳Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
- Conditions
- EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
- Interventions
- Drug: Sequential and maintenance icotinib
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT02194556
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, NanNing, Guangxi, China
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
- Conditions
- AdenocarcinomaEGFR Positive Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT02125240
- Locations
- 🇨🇳
304 Hospital of PLA, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
- Conditions
- EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
- Interventions
- Drug: Sequential Icotinib Plus Chemotherapy
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 192
- Registration Number
- NCT02103257
- Locations
- 🇨🇳
Urumqi General Hospital of Lanzhou Military Region General Hospital, Urumqi, Xinjiang, China
🇨🇳Jiangmen central hospital, Jiangmen, Guangdong, China
🇨🇳Medical Oncology,Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT02066870
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02062515
- Locations
- 🇨🇳
Sun Yat-sen Cancer Center, Guangzhou, Guangdong, China
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT02044328
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02027090
- Locations
- 🇨🇳
Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02024633
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang Univercity School of Medcine, Hangzhou, China
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- Drug: 2-year treatment with icotinibDrug: 1-year treatment with icotinib
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01929200
- Locations
- 🇨🇳
Beijing Cancer hospital, Beijing, China